RDEA3170 + Allopurinol + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gout and Hyperuricemia
Conditions
Gout and Hyperuricemia
Trial Timeline
Jan 5, 2014 → Mar 13, 2015
NCT ID
NCT02078219About RDEA3170 + Allopurinol + Placebo
RDEA3170 + Allopurinol + Placebo is a phase 2 stage product being developed by AstraZeneca for Gout and Hyperuricemia. The current trial status is completed. This product is registered under clinical trial identifier NCT02078219. Target conditions include Gout and Hyperuricemia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02078219 | Phase 2 | Completed |
Competing Products
20 competing products in Gout and Hyperuricemia